Form 8-K - Current report:
SEC Accession No. 0001193125-25-055666
Filing Date
2025-03-17
Accepted
2025-03-17 16:45:17
Documents
16
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d903231d8k.htm   iXBRL 8-K 28827
2 EX-99.1 d903231dex991.htm EX-99.1 152508
7 GRAPHIC g903231g0317231850597.jpg GRAPHIC 7150
  Complete submission text file 0001193125-25-055666.txt   380783

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA xoma-20250317.xsd EX-101.SCH 4583
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20250317_def.xml EX-101.DEF 14452
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20250317_lab.xml EX-101.LAB 24602
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20250317_pre.xml EX-101.PRE 15485
19 EXTRACTED XBRL INSTANCE DOCUMENT d903231d8k_htm.xml XML 7796
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39801 | Film No.: 25745231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)